Jakafi

Jakafi Uses, Dosage, Side Effects, Food Interaction and all others data.

Jakafi is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2 (IC 50 values of 3.3 nM and 2.8 nM for JAK1 and JAK2 enzymes, respectively). These mediate the signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function.MF and PV are myeloproliferative neoplasms known to be associated with dysregulated JAK1 and JAK2 signalling. The basis for the dysregulation is believed to include high levels of circulating cytokines that activate the JAK-STAT pathway, gain-of-function mutations such as JAK2V617F, and silencing of negative regulatory mechanisms. MF patients exhibit dysregulated JAK signalling regardless of JAK2V617F mutation status. Activating mutations in JAK2 (V617F or exon 12) are found in >95% of PV patients.Jakafi inhibits JAK-STAT signalling and cell proliferation of cytokine-dependent cellular models of haematological malignancies, as well as of Ba/F3 cells rendered cytokine-independent by expressing the JAK2V617F mutated protein, with IC 50 ranging from 80-320 nM.

Jakafi is an antineoplastic agent that inhibits cell proliferation, induces apoptosis of malignant cells, and reduces pro-inflammatory cytokine plasma levels by inhibiting JAK-induced phosphorylation of signal transducer and activator of transcription (STAT). Inhibition of STAT3 phosphorylation, which is used as a marker of JAK activity, by ruxolitinib is achieved at two hours after dosing which returned to near baseline by 10 hours in patients with myelofibrosis and polycythemia vera. In clinical trials, ruxolitinib reduced splenomegaly and improved symptoms of myelofibrosis. In a mouse model of myeloproliferative neoplasms, administration of ruxolitinib was associated with prolonged survival. Jakafi inhibits both mutant and wild-type JAK2 ; however, JAK2V617F mutation, which is often seen in approximately 50% of patients with myelofibrosis, was shown to reduce ruxolitinib sensitivity, which may also be associated with possible resistance to JAK inhibitor treatment.

Trade Name Jakafi
Availability Prescription only
Generic Ruxolitinib
Ruxolitinib Other Names Ruxolitinib
Related Drugs prednisone, methotrexate, mycophenolate mofetil, Deltasone, imatinib, Gleevec, Imbruvica, ibrutinib, Jakafi, Besremi
Weight 10mg, 15mg, 20mg, 25mg, 5mg,
Type Oral tablet
Formula C17H18N6
Weight Average: 306.365
Monoisotopic: 306.159294606
Protein binding

Ruxolitinib is approximately 97% bound to plasma proteins, mostly to albumin.

Groups Approved
Therapeutic Class Pyrrolopyrimidines
Manufacturer
Available Country United States,
Last Updated: September 19, 2023 at 7:00 am
Jakafi
Jakafi

Uses

Myelofibrosis (MF): Jakafi is used for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

Polycythaemia vera (PV): Jakafi is used for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea
Renal impairment: No specific dose adjustment is needed in patients with mild or moderate renal impairment.

Hepatic impairment: In patients with any hepatic impairment the recommended starting dose based on platelet count should be reduced by approximately 50% to be administered twice daily.

Elderly patients (≥65 years): No additional dose adjustments are recommended for elderly patients.

Paediatric population: The safety and efficacy of Jakafi in children and adolescents aged up to 18 years have not been established. No data are available

Jakafi is also used to associated treatment for these conditions: Graft Versus Host Disease, Acute, Post Essential Thrombocythaemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Primary Myelofibrosis, High risk Myelofibrosis, Intermediate risk Myelofibrosis, Refractory Polycythemia vera

How Jakafi works

The Janus kinase (JAK) family of protein tyrosine kinases comprises JAK1, JAK2, JAK3, and non-receptor tyrosine kinase 2 (TYK2). JAKs play a pivotal role in intracellular signalling pathways of various cytokines and growth factors essential to hematopoiesis, such as interleukin, erythropoietin, and thrombopoietin. JAKs have diverse functions: JAK1 and JAK3 promote lymphocyte differentiation, survival, and function, while JAK2 promotes signal transduction of erythropoietin and thrombopoietin. JAKs are in close proximity to the cytokine and growth factor receptor’s cytoplasmic region. Upon binding of cytokines and growth factors, JAKs are activated, undergoing cross-phosphorylation and tyrosine phosphorylation. This process also reveals selective binding sites for STATs, which are DNA-binding proteins that also bind to the cytoplasmic region of cytokine or growth factor receptors. Activated JAKs and STATs translocate to the nucleus as transcription factors to regulate gene expression of pro-inflammatory cytokines such as IL-6, IL-10, and nuclear factor κB (NF-κB). They also activate downstream pathways that promote erythroid, myeloid, and megakaryocytic development.

The molecular pathogenesis of myeloproliferative neoplasms is not fully understood; however, JAK2 is constitutively activated and the JAK-STAT signalling pathway becomes deregulated and aberrant. Jakafi is a selective and potent inhibitor of JAK2 and JAK1, with some affinity against JAK3 and TYK2. Anticancer effects of ruxolitinib are attributed to its inhibition of JAKs and JAK-mediated phosphorylation of STAT3. By downregulating the JAK-STAT pathway, ruxolitinib inhibits myeloproliferation and suppresses the plasma levels of pro-inflammatory cytokines such as IL-6 and TNF-α.

Activated JAKs are also implicated in graft-versus-host-disease (GVHD), which is a severe immune complication of allogeneic hematopoietic cell transplantation GVHD is associated with significant morbidity and mortality, especially for patients who do not respond well to corticosteroid therapy. Activated JAKS stimulate T-effector cell responses, leading to increased proliferation of effector T cells and heightened production of pro-inflammatory cytokines. By blocking JAK1 and JAk2, ruxolitinib inhibits donor T-cell expansion and suppresses pro-inflammatory responses.

Dosage

Jakafi dosage

The recommended starting dose of ruxolitinib in MF is 15 mg twice daily for patients with a platelet count between 100,000/mm 3 and 200,000/mm 3 and 20 mg twice daily for patients with a platelet count of >200,000/mm 3 . The recommended starting dose of ruxolitinib in PV is 10 mg given orally twice daily.

There is limited information to recommend a starting dose for patients with platelet counts between 50,000/mm 3 and <100,000/mm 3 . The maximum recommended starting dose in these patients is 5 mg twice daily and the patients should be titrated cautiously.

Jakafi is to be taken orally, with or without food. If a dose is missed, the patient should not take an additional dose, but should take the next usual prescribed dose.

Toxicity

The oral LD50 was 250 mg/kg.

Single doses of ruxolitinib up to 200 mg were tolerated well. Higher doses than recommended repeat doses are associated with myelosuppression, including leukopenia, anemia, and thrombocytopenia. There is no known antidote for overdoses with ruxolitinib: it is recommended that patients are given appropriate supportive treatment. Hemodialysis is not expected to enhance the elimination of ruxolitinib.

Food Interaction

  • Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of ruxolitinib.
  • Exercise caution with St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce the serum levels of ruxolitinib.
  • Take with or without food. A high-fat, high-calorie meal had negligible effects on the pharmacokinetics of ruxolitinib.

[Moderate] GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of ruxolitinib.

The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.

MANAGEMENT: Patients treated with ruxolitinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.

Jakafi may be administered with or without food.

Jakafi Cholesterol interaction

[Moderate] The use of ruxolitinib may increase total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides.

It is recommended to assess lipid parameters approximately 8-12 weeks following initiation of therapy and to monitor and treat per clinical guidelines for the management of hyperlipidemia.

Care should be exercised when using this agent in patients with lipids disorders.

Volume of Distribution

The mean volume of distribution (%coefficient of variation) at steady-state is 72 L (29%) in patients with myelofibrosis and 75 L (23%) in patients with polycythemia vera. It is not known whether ruxolitinib crosses the blood-brain barrier.

Elimination Route

Following oral administration, ruxolitinib undergoes rapid absorption and the peak concentrations are reached within one hour after administration. Over a single-dose range of 5 mg to 200 mg, the mean maximal plasma concentration (Cmax) increases proportionally. Cmax ranged from 205 nM to 7100 nM and AUC ranged from 862 nM x hr to 30700 nM x hr. Tmax ranges from one to two hours following oral administration. Oral bioavailability is at least 95%.

Half Life

The mean elimination half-life of ruxolitinib is approximately 3 hours and the mean half-life of its metabolites is approximately 5.8 hours.

Clearance

Jakafi clearance (% coefficient of variation) is 17.7 L/h in women and 22.1 L/h in men with myelofibrosis. Drug clearance was 12.7 L/h (42%) in patients with polycythemia vera and 11.9 L/h (43%) in patients with acute graft-versus-host disease.

Elimination Route

Following oral administration of a single radiolabeled dose of ruxolitinib, the drug was mainly eliminated through metabolism. About 74% of the total dose was excreted in urine and 22% was excreted in feces, mostly in the form of hydroxyl and oxo metabolites of ruxolitinib. The unchanged parent drug accounted for less than 1% of the excreted total radioactivity.

Pregnancy & Breastfeeding use

Contraindicated in pregnancy & lactation. There are no data from the use of ruxolitinib in pregnant women. Animal studies have shown that ruxolitinib is embryotoxic and foetotoxic. 

ruxolitinib must not be used during breast-feeding and breast-feeding should therefore be discontinued when treatment is started. It is unknown whether ruxolitinib and/or its metabolites are excreted in human milk. A risk to the breast-fed child cannot be excluded. Available pharmacodynamic/toxicological data in animals have shown excretion of ruxolitinib and its metabolites in milk

Fertility: There are no human data on the effect of ruxolitinib on fertility. In animal studies, no effect on fertility was observed.

Contraindication

Hypersensitivity to the active substance or to any of the excipients

Acute Overdose

There is no known antidote for overdoses with Jakafi. Single doses up to 200 mg have been given with acceptable acute tolerability. Higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anaemia and thrombocytopenia. Appropriate supportive treatment should be given. Haemodialysis is not expected to enhance the elimination of ruxolitinib.

Storage Condition

Do not store above 30°C.

Innovators Monograph

You find simplified version here Jakafi

Jakafi contains Ruxolitinib see full prescribing information from innovator Jakafi Monograph, Jakafi MSDS, Jakafi FDA label

http://classyfire.wishartlab.com/tax_nodes/C0000000
http://classyfire.wishartlab.com/tax_nodes/C0000002
http://classyfire.wishartlab.com/tax_nodes/C0001799
http://classyfire.wishartlab.com/tax_nodes/C0004415
http://classyfire.wishartlab.com/tax_nodes/C0004415
http://classyfire.wishartlab.com/tax_nodes/C0000075
http://classyfire.wishartlab.com/tax_nodes/C0000090
http://classyfire.wishartlab.com/tax_nodes/C0000087
http://classyfire.wishartlab.com/tax_nodes/C0004144
http://classyfire.wishartlab.com/tax_nodes/C0000362
http://classyfire.wishartlab.com/tax_nodes/C0004139
http://classyfire.wishartlab.com/tax_nodes/C0004557
http://classyfire.wishartlab.com/tax_nodes/C0004150
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:66919
http://www.genome.jp/dbget-bin/www_bget?drug:D09959
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=25126798
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=175427129
https://www.chemspider.com/Chemical-Structure.25027389.html
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355501
https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1193326
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=66919
https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1789941
https://zinc.docking.org/substances/ZINC000043207851
http://www.pharmgkb.org/drug/PA166123386
https://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/RXT
http://www.rxlist.com/jakafi-drug.htm
https://www.drugs.com/mtm/ruxolitinib.html
https://en.wikipedia.org/wiki/Ruxolitinib
*** Taking medicines without doctor's advice can cause long-term problems.
Share